LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (LXRX) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2015 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
LXRX on Nasdaq
Shares outstanding
427,442,892
Price per share
$1.50
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
259,589,213
Total reported value
$298,525,400
% of total 13F portfolios
0%
Share change
+4,425,028
Value change
+$4,953,621
Number of holders
117
Price from insider filings
$1.50
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (LXRX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Invus Global Management, LLC 36% $177,944,476 154,734,327 Artal Participations S.a r.l. 29 Jan 2026
FMR LLC 10% +9% $26,696,274 +$2,516,037 38,137,535 +10% FMR LLC 30 Jun 2025

As of 31 Dec 2025, 117 institutional investors reported holding 259,589,213 shares of LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (LXRX). This represents 61% of the company’s total 427,442,892 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (LXRX) together control 60% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Artal Group S.A. 32% 136,180,481 0% 22% $156,607,553
Siren, L.L.C. 9.1% 38,918,903 0% 1.3% $44,756,738
FMR LLC 8.9% 37,834,207 -2.2% 0% $43,509,338
VANGUARD GROUP INC 2.2% 9,606,549 +0.89% 0% $11,047,532
MILLENNIUM MANAGEMENT LLC 1.1% 4,821,733 +26% 0% $5,544,993
BlackRock, Inc. 0.75% 3,192,448 -6% 0% $3,671,316
UBS Group AG 0.7% 3,007,237 +752% 0% $3,458,322
Sessa Capital IM, L.P. 0.7% 3,000,000 0% 0.07% $3,450,000
GEODE CAPITAL MANAGEMENT, LLC 0.58% 2,500,022 +4.3% 0% $2,876,410
CIBC Private Wealth Group LLC 0.46% 1,950,000 -19% 0% $2,242,500
JANE STREET GROUP, LLC 0.4% 1,724,304 +278% 0% $1,982,950
CITADEL ADVISORS LLC 0.4% 1,710,975 -35% 0% $1,967,621
MARSHALL WACE, LLP 0.3% 1,262,367 0% $1,451,722
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.28% 1,207,242 +25% 0% $1,388,329
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.25% 1,055,123 -7.8% 0% $1,213,391
GSA CAPITAL PARTNERS LLP 0.23% 996,235 -17% 0.1% $1,146,000
GOLDMAN SACHS GROUP INC 0.22% 921,204 +1452% 0% $1,059,385
Hennion & Walsh Asset Management, Inc. 0.21% 901,222 +16% 0.04% $1,036,405
STATE STREET CORP 0.21% 884,738 +0.52% 0% $1,017,449
Ishara Investments LP 0.21% 880,000 0% 1.2% $1,012,000
ACADIAN ASSET MANAGEMENT LLC 0.15% 640,130 +1635% 0% $732,000
TWO SIGMA INVESTMENTS, LP 0.15% 637,308 +14% 0% $732,904
NORTHERN TRUST CORP 0.1% 412,164 +11% 0% $473,989
Compagnie Lombard Odier SCmA 0.1% 410,000 0% 0.01% $471,500
Point72 Asset Management, L.P. 0.07% 284,025 0% $326,629

Institutional Holders of LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (LXRX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 259,589,213 $298,525,400 +$4,953,621 $1.15 117
2025 Q3 255,139,258 $344,428,817 -$1,111,792 $1.35 121
2025 Q2 256,310,843 $242,983,204 -$6,845,383 $0.95 121
2025 Q1 265,818,368 $122,485,430 -$18,132,306 $0.46 124
2024 Q4 297,662,439 $220,126,714 -$8,084,075 $0.74 124
2024 Q3 288,616,985 $453,067,592 -$48,604,221 $1.57 134
2024 Q2 278,343,151 $467,625,172 +$175,856,984 $1.68 121
2024 Q1 171,815,966 $412,351,239 -$24,970,122 $2.40 114
2023 Q4 182,858,180 $279,771,925 -$6,759,847 $1.53 103
2023 Q3 188,793,708 $205,786,015 -$5,677,228 $1.09 109
2023 Q2 191,326,157 $438,152,499 +$104,558,326 $2.29 121
2023 Q1 145,600,839 $353,808,486 -$2,997,119 $2.43 102
2022 Q4 146,885,188 $280,547,551 -$3,977,447 $1.91 100
2022 Q3 148,905,062 $357,360,311 +$72,603,615 $2.40 98
2022 Q2 118,779,098 $220,940,693 -$2,430,736 $1.86 82
2022 Q1 120,193,264 $251,304,091 -$5,565,361 $2.09 100
2021 Q4 121,559,642 $478,894,149 -$1,466,109 $3.94 108
2021 Q3 121,205,281 $583,005,732 +$17,343,707 $4.81 96
2021 Q2 117,708,489 $540,207,653 +$2,119,118 $4.59 105
2021 Q1 121,214,904 $711,532,085 +$117,190 $5.87 103
2020 Q4 122,029,255 $417,334,864 +$65,690,726 $3.42 100
2020 Q3 104,248,250 $150,106,719 -$5,093,677 $1.44 83
2020 Q2 107,177,053 $213,813,923 +$4,797,305 $1.99 99
2020 Q1 104,815,254 $204,388,139 -$17,170,082 $1.95 107
2019 Q4 107,178,320 $444,778,336 +$20,431,577 $4.15 110
2019 Q3 102,423,092 $308,322,526 -$29,982,037 $3.01 95
2019 Q2 105,227,688 $661,832,362 +$7,044,227 $6.29 105
2019 Q1 104,271,703 $579,706,451 -$6,638,791 $5.56 112
2018 Q4 105,373,335 $699,630,313 -$17,077,199 $6.64 117
2018 Q3 107,498,975 $1,147,115,789 -$30,046,816 $10.67 114
2018 Q2 104,426,400 $1,253,163,056 -$371,540 $12.00 114
2018 Q1 109,754,416 $939,672,485 -$14,099,435 $8.57 118
2017 Q4 111,338,432 $1,100,040,141 -$44,224,810 $9.88 123
2017 Q3 110,485,325 $1,357,861,811 -$5,704,402 $12.29 130
2017 Q2 110,542,385 $1,818,248,643 +$18,151,870 $16.45 129
2017 Q1 109,854,396 $1,575,293,760 +$120,009,363 $14.34 130
2016 Q4 106,295,065 $1,470,204,819 -$2,532,260 $13.83 140
2016 Q3 106,140,794 $1,917,259,558 +$249,235 $18.07 138
2016 Q2 110,750,409 $1,589,249,524 +$1,094,261 $14.35 134
2016 Q1 110,808,225 $1,323,993,000 +$13,960,287 $11.95 126
2015 Q4 109,649,652 $1,459,682,001 +$54,951,710 $13.31 116
2015 Q3 105,860,530 $1,136,914,006 +$98,139,625 $10.74 99
2015 Q2 96,818,089 $779,385,263 +$779,385,260 $8.05 86